In particular, our findings revealing circulating MDK as a biomarker that reflects reduced tumor burden after BO‐110 treatment may prove useful to assess the antitumoral activity of this compound beyond less specific IFN‐associated markers. This evidence concerns the gene IFNA1 and neoplasm.